Clinical Trials Browser

Phase 3 × INDUSTRY × rasburicase × Clear all

NCT00607152 2014-05-08

Rasburicase (Fasturtec) Registration Trial

Phase 3 Terminated

Hyperuricemia

NCT00230178 2010-01-12

Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome

Phase 3 Completed

280 enrolled 10 charts

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphoma, Myelodysplastic Syndromes, Neoplasms, Tumor Lysis Syndrome, Hyperuricemia